Arrhythmias & electrophysiologyCohort study

Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade

CirculationPublished

  • Multicohort observational genetic association study
  • 3 cohorts (FinnGen, UK Biobank, Health 2000)

Authors' conclusion

The SCN5A T220I variant, consistent with a previously described weak loss-of-function effect, acted like a genetic proxy for cardiac sodium channel blockade.

Study context

Population
Individuals in FinnGen, UK Biobank and Health 2000
Participants
>1 million individuals · 3 cohorts
Exposure
SCN5A T220I carriers vs non-carriers

Main finding

AF

Cause-specific hazard ratio

0.56

95% CI 0.50–0.63

P < 0.0001

T220I vs Non-carriers
cause-specific HR 0.56 (95% CI 0.50–0.63); P < 0.0001

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeHR (95% CI)P value
Death from cardiac arrhythmia0.65 (0.46–0.92)P = 0.015
Outcomedifference (ms) (95% CI)P value
QT interval (Health 2000, n=3188) · replicated in UK Biobank (n=66 616)−7.49 (−10.07 to −4.91)P = 0.0037
OutcomeHRP value
Overall mortality0.92P = 0.27

Other arrhythmias, HF, dilated cardiomyopathy, AF polygenic score

Protective against ventricular premature depolarization or VT
Protected from (left) HF and dilated cardiomyopathy
Could lower a high polygenic score for AF to population average

Safety

Conduction-slowing conditions and post-MI mortality

Increased susceptibility to conduction-slowing conditions, such as sick sinus syndrome (mostly in older age groups)
Increased mortality risk after MI, normalized to baseline 10 to 15 years after MI

Original publication

Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. Circulation. Published 24 November 2025. doi:10.1161/circulationaha.125.075057

Summarised from the published abstract; every number is checked against it